Medulloblastoma - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Medulloblastoma - Pipeline Review, H1 2018’, provides an overview of the Medulloblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Medulloblastoma

The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects

The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Medulloblastoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Medulloblastoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Janpix Inc

Lipocure Ltd

MacroGenics Inc

Millennium ...

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Janpix Inc

Lipocure Ltd

MacroGenics Inc

Millennium Pharmaceuticals Inc

Moleculin Biotech Inc

NewLink Genetics Corp

Novartis AG

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Senhwa Biosciences Inc

Shionogi & Co Ltd

Stemline Therapeutics Inc

TheraBiologics Inc

ThromboGenics NV

VBI Vaccines Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Medulloblastoma – Overview 6

Medulloblastoma – Therapeutics Development 7

Medulloblastoma – Therapeutics Assessment 14

Medulloblastoma – ...

Table of Contents

Table of Contents 2

Introduction 5

Medulloblastoma – Overview 6

Medulloblastoma – Therapeutics Development 7

Medulloblastoma – Therapeutics Assessment 14

Medulloblastoma – Companies Involved in Therapeutics Development 22

Medulloblastoma – Drug Profiles 33

Medulloblastoma – Dormant Projects 219

Medulloblastoma – Product Development Milestones 220

Appendix 228

List of Tables

List of Tables

Number of Products under Development for Medulloblastoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Medulloblastoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Medulloblastoma – Pipeline by Bayer AG, H1 2018

Medulloblastoma – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Medulloblastoma – Pipeline by Bristol-Myers Squibb Co, H1 2018

Medulloblastoma – Pipeline by Celgene Corp, H1 2018

Medulloblastoma – Pipeline by DelMar Pharmaceuticals Inc, H1 2018

Medulloblastoma – Pipeline by Ignyta Inc, H1 2018

Medulloblastoma – Pipeline by IMPACT Therapeutics Inc, H1 2018

Medulloblastoma – Pipeline by Janpix Inc, H1 2018

Medulloblastoma – Pipeline by Lipocure Ltd, H1 2018

Medulloblastoma – Pipeline by MacroGenics Inc, H1 2018

Medulloblastoma – Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Medulloblastoma – Pipeline by Moleculin Biotech Inc, H1 2018

Medulloblastoma – Pipeline by NewLink Genetics Corp, H1 2018

Medulloblastoma – Pipeline by Novartis AG, H1 2018

Medulloblastoma – Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Medulloblastoma – Pipeline by Progenics Pharmaceuticals Inc, H1 2018

Medulloblastoma – Pipeline by Senhwa Biosciences Inc, H1 2018

Medulloblastoma – Pipeline by Shionogi & Co Ltd, H1 2018

Medulloblastoma – Pipeline by Stemline Therapeutics Inc, H1 2018

Medulloblastoma – Pipeline by TheraBiologics Inc, H1 2018

Medulloblastoma – Pipeline by ThromboGenics NV, H1 2018

Medulloblastoma – Pipeline by VBI Vaccines Inc, H1 2018

Medulloblastoma – Pipeline by Vyriad Inc, H1 2018

Medulloblastoma – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Medulloblastoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Medulloblastoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports